Blood Reviews
Volume 21, Issue 5 , Pages 255-265 , September 2007

Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma

References 

  1. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol. 2006;134:573–589
  2. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis of monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564–569
  3. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of Monoclonal Gammopathy of Undetermined Significance. N Engl J Med. 2006;354:1362–1369
  4. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later.[see comment]. Mayo Clinic Proceedings. 2004;79:859–866
  5. Weber D, Wang LM, Delasalle K, Smith T, Alexanian R. Risk factors for early progression of asymptomatic multiple myeloma. The Hematology Journal. 2003;4(Suppl 1):S31
  6. Wang M, Alexanian R, Delasalle K, Weber D. Abnormal, MRI of spine is the dominant risk factor for early progression of asymptomatic multiple myeloma. Blood. 2003;102:687a
  7. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clinical Chemistry. 2002;48:1437–1444
  8. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet. 2003;361:489–491
  9. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood. 2001;97:2900–2902
  10. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. British Journal of Haematology. 2003;122:78–84
  11. Abraham RS, Clark RJ, Bryant SC, et al. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem. 2002;48:655–657
  12. Jego G, Bataille R, Geffroy-Luseau A, Descamps G, Pellat-Deceunynck C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. 2006;20:1130–1137
  13. Bohnhorst J, Rasmussen T, Moen SH, et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. 2006;20:1138–1144
  14. Mantovani A, Garlanda C. Inflammation and multiple myeloma: the Toll connection. 2006;20:937–938
  15. van de Donk NW, Lokhorst HM, Bloem AC. Growth factors and antiapoptotic signaling pathways in multiple myeloma. Leukemia. 2005;19:2177–2185
  16. Perez-Andres M, Almeida J, Martin-Ayuso M, et al. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia. 2005;19:449–455
  17. Rawstron AC, Fenton JA, Ashcroft J, et al. The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood. 2000;96:3880–3886
  18. Amara S, Dezube BJ, Cooley TP, Pantanowitz L, Aboulafia DM. HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients.[see comment]. Clinical Infectious Diseases. 2006;43:1198–1205
  19. Dezube BJ, Aboulafia DM, Pantanowitz L. Plasma cell disorders in HIV-infected patients: from benign gammopathy to multiple myeloma. AIDS Reader. 2004;14:372–374
  20. Passweg J, Thiel G, Bock HA. Monoclonal gammopathy after intense induction immunosuppression in renal transplant patients. Nephrology Dialysis Transplantation. 1996;11:2461–2465
  21. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Research. 2004;64:1546–1558
  22. Kyle RA, Rajkumar SV. Multiple Myeloma. N Engl J Med. 2004;351:1860–1873
  23. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nature Reviews Cancer. 2002;2:175–187
  24. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001;20:5611–5622
  25. Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002;100:1417–1424
  26. Drach J, Angerler J, Schuster J, et al. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood. 1995;86:3915–3921
  27. Fonseca R, Aguayo P, Ahmann GJ, et al. Translocations at 14q32 are common in patients with the monoclonal gammopathy of undetermined significance (MGUS) and involve several partner chromosomes. Blood. 1999;94(Suppl 1):663a;A 2943
  28. Rajkumar SV. MGUS and Smoldering Multiple Myeloma: Update on Pathogenesis, Natural History, and Management. Hematology (Am Soc Hematol Educ Program). 2005;2005:340–345
  29. Chng WJ, Van Wier SA, Ahmann GJ, et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS 10.1182/blood-2005-02-0761. Blood. 2005;106:2156–2161
  30. Magrangeas F, Lode L, Wuilleme S, Minvielle S, Avet-Loiseau H. Genetic heterogeneity in multiple myeloma. Leukemia. 2005;19:191–194
  31. Kaufmann H, Ackermann J, Baldia C, et al. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia. 2004;18:1879–1882
  32. Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006;108:1724–1732
  33. Rajkumar SV, Mesa RA, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res. 2002;8:2210–2216
  34. Galea HR, Cogne M. GM-CSF and IL-12 production by malignant plasma cells promotes cell-mediated immune responses against monoclonal Ig determinants in a light chain myeloma model. Clinical & Experimental Immunology. 2002;129:247–253
  35. Vacca A, Ria R, Ribatti D, et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica. 2003;
  36. Kumar S, Fonseca R, Dispenzieri A, et al. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood. 2003;101:1715–1717
  37. Kumar S, Witzig TE, Timm M, et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: Evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood. 2004;104:1159–1165
  38. Kumar S, Witzig TE, Timm M, et al. Expression of VEGF and its receptors by myeloma cells. Leukemia. 2003;17:2025–2031
  39. Kumar S, Witzig TE, Wellik L, Greipp PR, Rajkumar SV. Effect of Thalidomide Therapy on Bone marrow Angiogenesis in Multiple Myeloma. Leukemia. 2004;18:624–627
  40. Roodman GD. Role of the bone marrow microenvironment in multiple myeloma. Journal of Bone & Mineral Research. 2002;17:1921–1925
  41. Roodman GD. Mechanisms of bone metastasis.[see comment]. New England Journal of Medicine. 2004;350:1655–1664
  42. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.[see comment]. New England Journal of Medicine. 2003;349:2483–2494
  43. Kyle RA, Rajkumar SV. Plasma Cell Disorders. In:  Goldman L,  Ausiello D editor. Cecil Textbook of Medicine. 22nd ed.. Philadelphia: W. B. Saunders; 2004;p. 1184–1195
  44. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of Monoclonal Gammopathy of Undetermined Significance (MGUS) among Olmsted County, MN Residents 50 Years of Age. Blood. 2003;102:934a;A3476
  45. Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2006;107:904–906
  46. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS). Blood. 2005;106:812–817
  47. Kyle RA. “Benign” monoclonal gammopathy–after 20 to 35 years of follow-up. Mayo Clinic Proceedings. 1993;68:26–36
  48. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–757
  49. Rajkumar SV, Dispenzieri A, Fonseca R, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia. 2001;15:1274–1276
  50. Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol. 2002;20:1625–1634
  51. Kumar S, Rajkumar SV, Kyle RA, et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol. 2005;23:5668–5674
  52. Barosi G, Boccadoro M, Cavo M, et al. Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica. 2004;89:717–741
  53. Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood. 2000;96:2037–2044
  54. Ross FM, Ibrahim AH, Vilain-Holmes A, et al. Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. Leukemia. 2005;19:1634–1642
  55. Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med. 1980;302:1347–1349
  56. Witzig TE, Kyle RA, WM OF, Greipp PR. Detection of peripheral blood plasma cells as a predictor of disease course in patients with smoldering multiple myeloma. British Journal of Haematology. 1994;87:266–272
  57. Kyle RA, Therneau TM, Rajkumar SV, et al. Update on smoldering multiple myeloma. Haematologica. 2005;90(Suppl 1):12
  58. Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rodjer S, Westin J. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I–a randomized study. Myeloma Group of Western Sweden. European Journal of Haematology. 1993;50:95–102
  59. Grignani G, Gobbi PG, Formisano R, et al. A prognostic index for multiple myeloma. British Journal of Cancer. 1996;73:1101–1107
  60. Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia. 2003;17:775–779
  61. Weber DM, Gavino M, Delasalle K, Rankin K, Giralt S, Alexanian R. Thalidomide alone or with dexamethasone for multiple myeloma. Blood. 1999;94(Suppl 1):604a;A 2686
  62. Bruno B, Giaccone L, Rotta M, Anderson K, Boccadoro M. Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside. Leukemia. 2005;19:1729–1738
  63. Richardson PG, Mitsiades CS, Hideshima T, Anderson KC. Novel biological therapies for the treatment of multiple myeloma. Best Practice & Research Clinical Haematology. 2005;18:619–634
  64. Kumar S, Raje N, Hideshima T, et al. Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs. Leukemia. 2005;19:1253–1261
  65. Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clinic Proceedings. 2006;81:693–703
  66. Rajkumar SV, Kyle RA. Multiple Myeloma: Diagnosis and Treatment. Mayo Clin Proc. 2005;80:1371–1382
  67. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Seminars in Oncology. 2003;30:110–115
  68. Baldini L, Goldaniga M, Guffanti A, et al. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom’s macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. Journal of Clinical Oncology. 2005;23:4662–4668
  69. Gobbi PG, Baldini L, Broglia C, et al. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?. Clinical Cancer Research. 2005;11:1786–1790
  70. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood. 2003;102:3759–3764

☆ SVR has received research support for the conduct of clinical trials at Mayo Clinic from Celgene Corp and Millennium Pharmaceuticals, Ltd. RAK has received consulting fees from Novartis Pharmaceuticals Corp, Celgene Corp, Millennium Pharmaceuticals, Ltd, Aeterna Zentaris Inc, and NeoRx Corp.

PII: S0268-960X(07)00003-3

doi: 10.1016/j.blre.2007.01.002

Blood Reviews
Volume 21, Issue 5 , Pages 255-265 , September 2007

Article Tools

* Image Usage & Resolution